Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04787991Phase 1Completed

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT04230499Phase 2Active Not Recruiting

Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Role: collaborator

NCT02297698Phase 2Completed

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Role: lead

NCT03066947Phase 1Completed

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Role: collaborator

NCT03618355Phase 1Completed

Trial of eRapa in Prostate Cancer Patients

Role: collaborator

NCT03014076Phase 1Completed

Immunotherapy Vaccine and Herceptin in Breast Cancer

Role: lead

All 6 trials loaded